According to CRI analysis, the global downstream processing market is expected to register a CAGR of~16.09% from 2021 to 2027and hold a value of ~USD 61,174.53million by 2027.

Downstream processing refers to the series of operations required to derive pure and homogeneous protein products from biological materials such as cells, tissue culture fluid, or plant tissues. There is a high demand for the end products extracted by downstream processing, owing to the increasing applications in of biopharmaceutical products. Thus, the downstream processing market is anticipated to observe significant growth during the forecast period.

Many market players are dominating the global downstream processing market. The prominent players are involved in strategic agreements,new product launches& developments,joint ventures, partnerships, collaborations, mergers & acquisitions, geographic expansion to sustain their market positions.For instance, in March 2021, Thermo Fisher Scientific, Inc. (US) announced that more than USD 600 million would be invested to expand its bioprocessing production capabilities through 2022 to meet short-term demands related to COVID-19 as well as long-term efforts to improve new vaccines and biologics for other conditions.

Regional Analysis

By region, North America is anticipated to dominate the global downstream processing market, owing to well-established research organizations involved in research activities, the presence of a high number of contract manufacturing organizations (CMOs), and the presence of a large number of pharmaceutical and biopharmaceutical companies. Moreover, the rise in R&D investments by public and private players in the healthcare sector further drives the market growth.

On the other hand, the European downstream processing market is driven by rising R&D expenditure by biopharmaceutical companies, increasing investments in the R&D sector, and the presence of key market players. For instance, in November 2019, Thermo Fisher Scientific, Inc. (US) announced that it is investing nearly USD 24 million in its Scotland site to expand global bioproduction capabilities with additional large-volume liquid manufacturing capacity for cell culture media.

Asia-Pacific is anticipated to be the fastest-growing market in the region over the assessment period due to growing and improving healthcare infrastructure, the establishment of research organizations, and increasing investments in biotechnology. In addition, factors such as the growing investments by key market players and the rapidly developing pharma and biopharma sector in the region are further driving the market.For instance, in April 2021, Asahi Kasei Corporation, a solution provider to the biologics manufacturing industry, expanded its business in China with the launch of Asahi Kasei Bioprocess (Shanghai) Co., Ltd (AKBC).The launch of AKBC facilitates business expansion in China by localizing inventory management and order processing for shorter delivery times.

Furthermore, the growth of the market in the rest of the World is attributed to the booming biotechnology sector and advancements in chromatographic techniques in the region.

Segmentation

The global downstream processing market has been segmented into technique, product, application, and end user.

By technique, the market has been segregated into cell disruption, solid-liquid separation, clarification/concentration, purification techniques, and formulation. The purification techniques segment is further sub-segmented into ion exchange, affinity exchange, hydrophobic interaction, size exclusion chromatography, and others. The purification techniques segment held a significant share of the market in 2020, as it is one of the vital steps in downstream processing and has high product differentiation.

Based on the product, the global downstream processing market has been classified as chromatography columns &resins, filters, membrane adsorbers, and others. The chromatography columns &resinsis one of the most widely used product and was estimated to be the largest segment in 2020.

Based on application, the downstream processing market is segmented into antibiotic production, hormone production, antibodies production, vaccine production, and others. Antibiotic production is one of the vital applications owing to increasing infectious diseases. Furthermore, the ongoing pandemic has created a huge demand for vaccine production globally which further supports the growth of the market.

Based on the end user, the downstream processing market is segmented into biopharmaceutical manufacturers, contract manufacturing organizations, and others. The biopharmaceutical manufacturers segment held the largest market share in 2020 due to increased R&D activities and production of biologics at a large scale, along with the rapidly growing biopharmaceutical industry.

Key Players

Some of the key players in the global downstream processing market are Thermo Fisher Scientific Inc. (US), Sartorius Stedim Biotech S.A. (France), Merck Millipore (Germany), Danaher Corporation (US), 3M Company (US), Boehringer Ingelheim (Germany), Lonza Group AG (Switzerland), Eppendorf AG (Switzerland), Corning Incorporated (US), and Asahi Kasei Corporation (Japan).

Global Cell and Gene Therapy Manufacturing QC Market to Reach $5.92 Billion by 2030

The post Downstream Processing Market: The growing biopharmaceutical industry and increasing spending in medical researchare anticipated to boost market growth at a healthy CAGR of ~16.09% during the forecast period of 2021 to 2027 first appeared on CRI Report.